Highlights from the 2005 American Society of Clinical Oncology Prostate Cancer Symposium, Orlando, Florida.
Reddy
G Kesava
GK
Gibson
Tara Beers
TB
Hutson
Thomas
T
Marianni
Sara
S
Sartor
Oliver
O
D000135:Acid Phosphatase; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000068258:Bevacizumab; D001952:Bridged-Ring Compounds / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003713:Dendritic Cells / Q000276:immunology; D006801:Humans; D007167:Immunotherapy; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use; D009943:Organophosphorus Compounds / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000276:immunology / Q000473:pathology; D017027:Protein Tyrosine Phosphatases / Q000378:metabolism; D043823:Taxoids / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D001952:Bridged-Ring Compounds; D009942:Organometallic Compounds; D009943:Organophosphorus Compounds; D043823:Taxoids; C080625:taxane; D000068258:Bevacizumab; C061972:samarium Sm-153 lexidronam; D000135:Acid Phosphatase; C428439:prostatic acid phosphatase; D017027:Protein Tyrosine Phosphatases